DHR Stock Recent News

While Danaher (DHR) surpasses Q4 earnings and revenue estimates, its performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Biotechnology segment.

The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Danaher (DHR) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.90 per share. This compares to earnings of $2.87 per share a year ago.

Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Danaher's (DHR) Q4 earnings are likely to have been hurt by weakness in the Biotechnology and Diagnostics units owing to lower sales of COVID-related products. Improving supply chains and strong price realization are expected to have been positives.

Beyond analysts' top -and-bottom-line estimates for Danaher (DHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Danaher (DHR) closed the most recent trading day at $229.64, moving -0.53% from the previous trading session.

Danaher Corporation NYSE: DHR shares went into a tailspin when the Abcam deal came into question, but the dip turned out to be a buying opportunity in this life-sciences company. The dip hit bottom soon after, and even weak guidance could not lower the market.